Clinical Trial

Disease: Non-small Cell Lung Cancer, NSCLC, (NCT06097962)

Disease info:

Lung cancer is generally divided into two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), depending on the size of the affected cells when viewed under a microscope. NSCLC accounts for 85 % of all lung cancers, while SCLC accounts for the remaining 15 %.

Lung cancer may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, blood in the mucus, breathing problems, trouble swallowing or speaking, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Additional symptoms can develop if the cancer spreads (metastasises) into other tissues.

NSCLC is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell lung carcinoma. Adenocarcinoma arises from the cells that line the small air sacs located throughout the lungs. Squamous cell carcinoma arises from squamous cells that line the passages leading from the windpipe to the lungs (bronchi). Large cell carcinoma arises from epithelial cells that line the lungs. Large cell carcinoma encompasses non-small cell lung cancers that do not appear to be adenocarcinomas or squamous cell carcinomas. The 5-year survival rate for people with NSCLC is usually between 11 and 17 %, but this can be lower or higher depending on the subtype and stage of the cancer.

Frequency:
An estimated 226,650 people will be diagnosed with lung cancer in the United States in 2025.
Official title:
Exploratory Study of NK510 Combined With PD-1 Blockade in the Treatment of Relapsed and Refractory Advanced NSCLC
Who:

Contact 

Name: Jun Yan, PhD

Phone: +86 186 2166 8515

Email: yanjun@basetherapeutics.com

Contact Backup

Name: Tangfeng Lv

Phone Number: +86 139 5201 6932

Email: bairoushui@163.com

Sponsor:

Base Therapeutics (Shanghai) Co., Ltd.

Partners:

The General Hospital of Eastern Theater Command
 

Locations:

Jiangsu, China

General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China

Study start:
Jul. 1, 2023
Enrollment:
9
Gene editing method:
AccuBase® base editor
Type of edit:
Gene knockout and gene knock in
Gene:
Knockout of PD-1 and knock in of CD16
Delivery method:
- Ex-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced NSCLC. NK510 will be administered in combination with PD-1 blockade. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 expression,and EGFR,ROS1,ALK gene must be negative. The safety and efficacy of this treatment will be evaluated.

Last updated: Sep. 22, 2025
close
Search CRISPR Medicine